A carregar...

Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality

AIM: Patients with colorectal liver metastases (CRLM) benefit from liver resection. Bevacizumab is commonly used in these patients resulting in a greater number of patients receiving an operation for a potentially curative liver resection, with initially unresectable liver metastases. Our purpose wa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepat Oncol
Main Authors: Giakoustidis, Alexandros, Neofytou, Kyriakos, Khan, Aamir, Mudan, Satvinder
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095412/
https://ncbi.nlm.nih.gov/pubmed/30190972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.14.17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!